135 related articles for article (PubMed ID: 27372840)
1. Novel FXR (farnesoid X receptor) modulators: Potential therapies for cholesterol gallstone disease.
Yu DD; Andrali SS; Li H; Lin M; Huang W; Forman BM
Bioorg Med Chem; 2016 Sep; 24(18):3986-3993. PubMed ID: 27372840
[TBL] [Abstract][Full Text] [Related]
2. Glucagon-like peptide 1 analogue prevents cholesterol gallstone formation by modulating intestinal farnesoid X receptor activity.
Zhang Z; Du Z; Liu Q; Wu T; Tang Q; Zhang J; Huang C; Huang Y; Li R; Li Y; Zhao Y; Zhang G; Zhou J; Huang H; Fang Z; He J
Metabolism; 2021 May; 118():154728. PubMed ID: 33581130
[TBL] [Abstract][Full Text] [Related]
3. The effect of ursodeoxycholic acid on the relative expression of the lipid metabolism genes in mouse cholesterol gallstone models.
Fan N; Meng K; Zhang Y; Hu Y; Li D; Gao Q; Wang J; Li Y; Wu S; Cui Y
Lipids Health Dis; 2020 Jul; 19(1):158. PubMed ID: 32615989
[TBL] [Abstract][Full Text] [Related]
4. Ursodeoxycholic Acid Suppresses Lipogenesis in Mouse Liver: Possible Role of the Decrease in β-Muricholic Acid, a Farnesoid X Receptor Antagonist.
Fujita K; Iguchi Y; Une M; Watanabe S
Lipids; 2017 Apr; 52(4):335-344. PubMed ID: 28315136
[TBL] [Abstract][Full Text] [Related]
5. Regulation of ileal bile acid-binding protein expression in Caco-2 cells by ursodeoxycholic acid: role of the farnesoid X receptor.
Campana G; Pasini P; Roda A; Spampinato S
Biochem Pharmacol; 2005 Jun; 69(12):1755-63. PubMed ID: 15935148
[TBL] [Abstract][Full Text] [Related]
6. Coordinated induction of bile acid detoxification and alternative elimination in mice: role of FXR-regulated organic solute transporter-alpha/beta in the adaptive response to bile acids.
Zollner G; Wagner M; Moustafa T; Fickert P; Silbert D; Gumhold J; Fuchsbichler A; Halilbasic E; Denk H; Marschall HU; Trauner M
Am J Physiol Gastrointest Liver Physiol; 2006 May; 290(5):G923-32. PubMed ID: 16357057
[TBL] [Abstract][Full Text] [Related]
7. Differential activation of the human farnesoid X receptor depends on the pattern of expressed isoforms and the bile acid pool composition.
Vaquero J; Monte MJ; Dominguez M; Muntané J; Marin JJ
Biochem Pharmacol; 2013 Oct; 86(7):926-39. PubMed ID: 23928191
[TBL] [Abstract][Full Text] [Related]
8. Modification on ursodeoxycholic acid (UDCA) scaffold. discovery of bile acid derivatives as selective agonists of cell-surface G-protein coupled bile acid receptor 1 (GP-BAR1).
Sepe V; Renga B; Festa C; D'Amore C; Masullo D; Cipriani S; Di Leva FS; Monti MC; Novellino E; Limongelli V; Zampella A; Fiorucci S
J Med Chem; 2014 Sep; 57(18):7687-701. PubMed ID: 25162837
[TBL] [Abstract][Full Text] [Related]
9. Ursodeoxycholic acid is a GPBAR1 agonist and resets liver/intestinal FXR signaling in a model of diet-induced dysbiosis and NASH.
Carino A; Biagioli M; Marchianò S; Fiorucci C; Zampella A; Monti MC; Scarpelli P; Ricci P; Distrutti E; Fiorucci S
Biochim Biophys Acta Mol Cell Biol Lipids; 2019 Oct; 1864(10):1422-1437. PubMed ID: 31325638
[TBL] [Abstract][Full Text] [Related]
10. The bile acids, deoxycholic acid and ursodeoxycholic acid, regulate colonic epithelial wound healing.
Mroz MS; Lajczak NK; Goggins BJ; Keely S; Keely SJ
Am J Physiol Gastrointest Liver Physiol; 2018 Mar; 314(3):G378-G387. PubMed ID: 29351391
[TBL] [Abstract][Full Text] [Related]
11. Effect of common polymorphisms of the farnesoid X receptor and bile acid transporters on the pharmacokinetics of ursodeoxycholic acid.
Hu M; Fok BS; Wo SK; Lee VH; Zuo Z; Tomlinson B
Clin Exp Pharmacol Physiol; 2016 Jan; 43(1):34-40. PubMed ID: 26382575
[TBL] [Abstract][Full Text] [Related]
12. Computational discovery and experimental verification of farnesoid X receptor agonist auraptene to protect against cholestatic liver injury.
Gao X; Fu T; Wang C; Ning C; Kong Y; Liu Z; Sun H; Ma X; Liu K; Meng Q
Biochem Pharmacol; 2017 Dec; 146():127-138. PubMed ID: 28987596
[TBL] [Abstract][Full Text] [Related]
13. Bile acids induce the expression of the human peroxisome proliferator-activated receptor alpha gene via activation of the farnesoid X receptor.
Pineda Torra I; Claudel T; Duval C; Kosykh V; Fruchart JC; Staels B
Mol Endocrinol; 2003 Feb; 17(2):259-72. PubMed ID: 12554753
[TBL] [Abstract][Full Text] [Related]
14. Prevention of cholesterol gallstone disease by FXR agonists in a mouse model.
Moschetta A; Bookout AL; Mangelsdorf DJ
Nat Med; 2004 Dec; 10(12):1352-8. PubMed ID: 15558057
[TBL] [Abstract][Full Text] [Related]
15. UDCA and CDCA alleviate 17α-ethinylestradiol-induced cholestasis through PKA-AMPK pathways in rats.
Li X; Yuan Z; Liu R; Hassan HM; Yang H; Sun R; Zhang L; Jiang Z
Toxicol Appl Pharmacol; 2016 Nov; 311():12-25. PubMed ID: 27743861
[TBL] [Abstract][Full Text] [Related]
16. The glucocorticoid mometasone furoate is a novel FXR ligand that decreases inflammatory but not metabolic gene expression.
Bijsmans IT; Guercini C; Ramos Pittol JM; Omta W; Milona A; Lelieveld D; Egan DA; Pellicciari R; Gioiello A; van Mil SW
Sci Rep; 2015 Sep; 5():14086. PubMed ID: 26369990
[TBL] [Abstract][Full Text] [Related]
17. Ursodeoxycholic Acid (UDCA) Promotes Lactate Metabolism in Mouse Hepatocytes through Cholic Acid (CA) - Farnesoid X Receptor (FXR) Pathway.
Wang L; He HW; Zhou X; Long Y
Curr Mol Med; 2020; 20(8):661-666. PubMed ID: 31971110
[TBL] [Abstract][Full Text] [Related]
18. Hematopoietically expressed homeobox is a target gene of farnesoid X receptor in chenodeoxycholic acid-induced liver hypertrophy.
Xing X; Burgermeister E; Geisler F; Einwächter H; Fan L; Hiber M; Rauser S; Walch A; Röcken C; Ebeling M; Wright MB; Schmid RM; Ebert MP
Hepatology; 2009 Mar; 49(3):979-88. PubMed ID: 19072826
[TBL] [Abstract][Full Text] [Related]
19. Extending the structure-activity relationship of anthranilic acid derivatives as farnesoid X receptor modulators: development of a highly potent partial farnesoid X receptor agonist.
Merk D; Lamers C; Ahmad K; Carrasco Gomez R; Schneider G; Steinhilber D; Schubert-Zsilavecz M
J Med Chem; 2014 Oct; 57(19):8035-55. PubMed ID: 25255039
[TBL] [Abstract][Full Text] [Related]
20. Regulation of the human bile acid UDP-glucuronosyltransferase 1A3 by the farnesoid X receptor and bile acids.
Erichsen TJ; Aehlen A; Ehmer U; Kalthoff S; Manns MP; Strassburg CP
J Hepatol; 2010 Apr; 52(4):570-8. PubMed ID: 20189675
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
